210 related articles for article (PubMed ID: 16794639)
1. The US Food and Drug Administration perspective on cancer biomarker development.
Gutman S; Kessler LG
Nat Rev Cancer; 2006 Jul; 6(7):565-71. PubMed ID: 16794639
[TBL] [Abstract][Full Text] [Related]
2. Search for shortcuts on the critical path to market: US FDA perspectives from the diagnostic side.
Gutman S; Hackett J
Pharmacogenomics; 2006 Dec; 7(8):1223-7. PubMed ID: 17184209
[TBL] [Abstract][Full Text] [Related]
3. Predictive biomarkers and clinical evidence.
Jørgensen JT
Basic Clin Pharmacol Toxicol; 2021 May; 128(5):642-648. PubMed ID: 33665955
[TBL] [Abstract][Full Text] [Related]
4. US manufacturing guideline for IVD products.
Donawa M
Med Device Technol; 2000 Oct; 11(8):23-4. PubMed ID: 11185183
[TBL] [Abstract][Full Text] [Related]
5. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
Philip R; Carrington L; Chan M
Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
[TBL] [Abstract][Full Text] [Related]
6. FDA and CLIA oversight of advanced diagnostics and biomarker tests.
Terry SF
Genet Test Mol Biomarkers; 2010 Jun; 14(3):285-7. PubMed ID: 20578940
[No Abstract] [Full Text] [Related]
7. Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.
Dobbin KK; Cesano A; Alvarez J; Hawtin R; Janetzki S; Kirsch I; Masucci GV; Robbins PB; Selvan SR; Streicher HZ; Zhang J; Butterfield LH; Thurin M
J Immunother Cancer; 2016; 4():77. PubMed ID: 27891226
[TBL] [Abstract][Full Text] [Related]
8. Uncertainty Over DAT Testing.
Schmidt C
J Natl Cancer Inst; 2012 Oct; 104(19):1427-8. PubMed ID: 23008497
[No Abstract] [Full Text] [Related]
9. Predictive biomarkers in advance of a companion drug: ahead of their time?
Kelley RK; Atreya C; Venook AP; Febbo PG
J Natl Compr Canc Netw; 2012 Mar; 10(3):303-9. PubMed ID: 22393192
[TBL] [Abstract][Full Text] [Related]
10. FDA warning on HIV tests purchased on the Internet.
Rose VL
Am Fam Physician; 1999 Sep; 60(3):1026, 1029. PubMed ID: 10498126
[No Abstract] [Full Text] [Related]
11. [Diagnostic kits in parasitology: which controls?].
Rossi P
Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
[TBL] [Abstract][Full Text] [Related]
12. 2019 White Paper on Recent Issues in Bioanalysis: FDA Immunogenicity Guidance, Gene Therapy, Critical Reagents, Biomarkers and Flow Cytometry Validation (Part 3 - Recommendations on 2019 FDA Immunogenicity Guidance, Gene Therapy Bioanalytical Challenges, Strategies for Critical Reagent Management, Biomarker Assay Validation, Flow Cytometry Validation & CLSI H62).
Piccoli S; Mehta D; Vitaliti A; Allinson J; Amur S; Eck S; Green C; Hedrick M; Hopper S; Ji A; Joyce A; Litwin V; Maher K; Mathews J; Peng K; Safavi A; Wang YM; Zhang Y; Amaravadi L; Palackal N; Thankamony S; Beaver C; Bame E; Emrich T; Grimaldi C; Haulenbeek J; Joyce A; Kakkanaiah V; Lanham D; Maher K; Mayer A; Trampont PC; Vermet L; Dakappagari N; Fleener C; Garofolo F; Rogers C; Tangri S; Xu Y; Liang M; Rajadhyaksha M; Richards S; Schweighardt B; Purushothama S; Baltrukonis D; Brumm J; Cherry E; Delcarpini J; Gleason C; Kirshner S; Kubiak R; Pan L; Partridge M; Pedras-Vasconcelos J; Qu Q; Skibeli V; Saunders TS; Staack RF; Stubenrauch K; Torri A; Verthelyi D; Yan H; Gorovits B; Palmer R; Milton M; Long B; Corsaro B; Farrokhi V; Fiscella M; Henderson N; Jawa V; McNally J; Murphy R; Waldner H; Yang TY
Bioanalysis; 2019 Dec; 11(24):2207-2244. PubMed ID: 31820675
[TBL] [Abstract][Full Text] [Related]
13. Workshop Report: Crystal City VI-Bioanalytical Method Validation for Biomarkers.
Arnold ME; Booth B; King L; Ray C
AAPS J; 2016 Nov; 18(6):1366-1372. PubMed ID: 27514862
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Regulatory Aspects of Companion Diagnostic Development in Oncology.
Jørgensen JT; Hersom M
Clin Pharmacol Ther; 2018 Jun; 103(6):999-1008. PubMed ID: 29197081
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA analysis: is it ready for prime time?
Tsongalis GJ; Calin G; Cordelier P; Croce C; Monzon F; Szafranska-Schwarzbach AE
Clin Chem; 2013 Feb; 59(2):343-7. PubMed ID: 22935643
[No Abstract] [Full Text] [Related]
16. An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies.
Beaver JA; Tzou A; Blumenthal GM; McKee AE; Kim G; Pazdur R; Philip R
Clin Cancer Res; 2017 Mar; 23(6):1368-1372. PubMed ID: 27993967
[TBL] [Abstract][Full Text] [Related]
17. Analyte-specific reagents.
Press RD
Mol Diagn; 1999 Mar; 4(1):71. PubMed ID: 10229777
[No Abstract] [Full Text] [Related]
18. The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers.
Zhang Z; Chan DW
Cancer Epidemiol Biomarkers Prev; 2010 Dec; 19(12):2995-9. PubMed ID: 20962299
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of FDA licensed HIV assays using plasma from Cameroonian blood donors.
Lee S; Hu J; Tang S; Wood O; Francis K; Machuca A; Rios M; Daniel S; Vockley C; Awazi B; Zekeng L; Hewlett I
J Med Virol; 2006; 78 Suppl 1():S22-3. PubMed ID: 16622873
[TBL] [Abstract][Full Text] [Related]
20. From the Food and Drug Administration.
Henney JE
JAMA; 2000 Jan; 283(1):46. PubMed ID: 10632269
[No Abstract] [Full Text] [Related]
[Next] [New Search]
